How to Submit an IND in eCTD Format: A Step-by-Step Guide

Why the eCTD Format Matters for IND Submissions

The electronic Common Technical Document (eCTD) is the mandatory format for submitting Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA). As of May 2018, the FDA requires that all commercial INDs, including amendments and safety updates, be submitted electronically using eCTD specifications.

The eCTD ensures consistency, easier navigation, and efficient regulatory review. Non-eCTD submissions are now only permitted for emergency use INDs or under specific waivers. Failure to comply may result in Refuse-to-File (RTF) notices or submission rejections.

Sponsors unfamiliar with eCTD can benefit from browsing templates and format expectations published on platforms like EU Clinical Trials Register for global comparison.

Overview of eCTD Structure for INDs

The eCTD format is organized into five main modules, structured to present data consistently and logically:

• Module 1: Administrative and Product Information (Region-specific)
• Module 2: Overviews and Summaries
• Module 3: Quality (CMC)
• Module 4: Nonclinical Study Reports
• Module 5: Clinical Study Reports and Protocols

Sample Table: eCTD Module Summary for IND

eCTD Technical Specifications and Submission Components

Submitting in eCTD format involves more than converting PDFs. Submissions must adhere to FDA’s technical standards, including:

• Use of XML backbone and STF (Study Tagging Files)
• Folder naming conventions (e.g., “m1”, “m2”, “m3”)
• PDF specifications (bookmarked, searchable, hyperlinked)
• Correct use of metadata and submission envelope

Sponsors must validate the submission using eCTD validation tools before uploading through the FDA’s Electronic Submission Gateway (ESG).

Publishing and Lifecycle Management

Publishing refers to assembling and packaging all files for eCTD compliance. This includes:

• Granularity: Submitting files at the correct document level
• Lifecycle: Using “new,” “replace,” or “delete” operations correctly
• Hyperlinking: Cross-referencing between documents for reviewer ease
• Validation: Ensuring files pass FDA’s technical checks

Tools, Tips, and Common eCTD Errors to Avoid

Recommended Tools for eCTD Submission

Sponsors may use commercial publishing software or contract with vendors for eCTD submission. Some commonly used tools include:

• GlobalSubmit
• Extedo
• Lorenz docuBridge
• MasterControl
• eCTDXpress

It is essential that the chosen tool supports the FDA’s eCTD v3.2.2 standard and generates valid submission-ready packages.

Tips for First-Time eCTD Filers

• Begin with an eCTD template structure from a prior submission or mock sample
• Validate all documents using FDA-approved software before uploading
• Bookmark each PDF section (e.g., “3.2.P.4 – Control of Critical Steps”)
• Avoid scanned image files — use text-based PDFs
• Use consistent file naming conventions and metadata tags

First-time filers may consider submitting a mock or practice submission before the official IND filing to verify gateway connectivity and formatting.

Common eCTD Errors to Avoid

eCTD submissions are rejected more often due to formatting errors than scientific content. Key pitfalls include:

• Missing or incorrect envelope metadata
• Unbookmarked PDFs or broken internal hyperlinks
• Non-compliant filenames or folder structure
• Incorrect lifecycle operations (e.g., overwriting required files)
• Failure to validate submission before ESG upload

FDA provides a Technical Rejection Criteria document that outlines reasons a submission may be rejected at the gateway level.

Post-Submission Tracking and Regulatory Correspondence

Once submitted, sponsors will receive an acknowledgment from the FDA ESG. It is important to:

• Monitor for “MDN” (Message Delivery Notification)
• Respond promptly to FDA queries or hold letters
• Track submission sequence numbers for cumulative documentation

The regulatory team should maintain a master tracker with submission dates, sequence numbers, and linked FDA feedback for audit readiness.

Global Alignment: eCTD Use Beyond the U.S.

eCTD has become the global standard for regulatory submissions. It is accepted or mandated in regions including:

• Europe (EMA)
• Canada (Health Canada)
• Japan (PMDA)
• Australia (TGA)

Harmonizing your eCTD format across regions can reduce rework, speed up timelines, and simplify lifecycle management.

Conclusion: Building a Compliant eCTD Submission for IND

The eCTD format is no longer optional for commercial IND submissions. Proper planning, publishing, validation, and compliance with FDA technical standards are essential for avoiding costly rejections and regulatory delays.

Whether you’re submitting your first IND or managing a global development program, investing in robust eCTD tools, training, and submission infrastructure will streamline your regulatory journey and ensure audit-ready documentation at every stage.